Abstract: Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

Abstract: Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

Abstract: Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

Abstract: A method of synthesizing copolymers is provided. The method can include coupling a degradable polymer to a poly(amino acid) and then deprotecting the copolymer if the poly(amino acid) contains protected side chains. Copolymer compositions are provided. These compositions include PLGA-PLL copolymers, PLGA-PLL-cbz copolymers, and copolymers of a polyester with a carboxylic acid end group coupled to a poly(amino acid) with an amine group. The compositions may include therapeutic blends and formulations of copolymers.

Abstract: A method of synthesizing copolymers is provided. The method can include coupling a degradable polymer to a poly(amino acid) and then deprotecting the copolymer if the poly(amino acid) contains protected side chains. Copolymer compositions are provided. These compositions include PLGA-PLL copolymers, PLGA-PLL-cbz copolymers, and copolymers of a polyester with a carboxylic acid end group coupled to a poly(amino acid) with an amine group. The compositions may include therapeutic blends and formulations of copolymers.

Abstract: Polymers comprising a polymer backbone comprising one or more degradable units are described. The polymer may additionally comprise two or more polymer segments comprising radically (co)polymerizable vinyl monomer units. The degradable units may be independently selected from, but not limited to, at least one of hydrodegradable, photodegradable and biodegradable units between the polymer segments and dispersed along the polymer backbone. The degradable units may be derived from one or more monomers comprising a heterocyclic ring that is capable of undergoing radical ring opening polymerization, a coupling agent, or from a polymerization initiator, radically polymerizable monomers, as well as other reactive sources. Embodiments of the degradable polymer of claim are capable of degrading by at least one of a hydrodegradation, photodegradation or biodegradation mechanisms to form at least one of telechelic oligomer and telechelic polymeric fragments of the polymer.